Company news
Supernus Pharmaceuticals, Inc. news in 2019
Supernus Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
December 8, 2019
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD
November 10, 2019
Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
November 4, 2019
Supernus to Host Third Quarter 2019 Earnings Conference Call
October 23, 2019
Supernus to Present at the 2019 Cantor Global Healthcare Conference
September 24, 2019
Decks in 2019
- Corporate Update (March 2019)
Corporate update · 14 slides · Mar 28, 2019